Insilico Medicine, one of the more visible companies applying artificial intelligence to drug discovery, is having a busy stretch on two fronts at once: partnerships and podiums.
On the partnership side, The Pharma Letter reports that Insilico and CMS have deepened their AI drug discovery tie-up with a new central nervous system program. CNS is one of the harder areas in pharma, where drug candidates have historically failed at high rates, so it is a notable place to point an AI-driven discovery engine.
On the conference side, Insilico is anchoring the field's calendar. According to EurekAlert!, Insilico Medicine and Eli Lilly will anchor the 13th Aging Research & Drug Discovery (ARDD) meeting at the David Rubenstein Treehouse at Harvard University. A separate EurekAlert! announcement says Insilico has released the ARDD 2026 program, bringing global leaders in longevity biotechnology to Boston.
The company is also looking east. EurekAlert! reports Insilico Medicine will showcase its longevity and AI drug discovery work at BIO Asia-Taiwan 2026, putting the same pitch in front of the Asian biotech and investment community.
Taken together, the items sketch a strategy rather than a single announcement. A company built on the claim that machine learning can find drug targets and design molecules faster than traditional methods is simultaneously signing deeper pharma partnerships and positioning itself at the center of the longevity research community, alongside a major incumbent in Eli Lilly.
It matters because the credibility of AI drug discovery still rests on whether these programs produce medicines that work in patients, and partnerships like the CMS CNS effort are the kind of bets that will eventually answer that question.